April 19 2011 Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis

San Diego, CA – Apr 19, 2011 — Amira Pharmaceuticals, Inc.  announced today that AM152, the company’s lead LPA1 antagonist, has been  granted an orphan drug designation by the U.S. Food and Drug Administration for  the treatment of idiopathic pulmonary fibrosis. Commonly referred to as IPF, this  fibrotic disease affects the lungs of patients and their ability to breathe.

See Full Article:
http://www.amirapharm.com/articles/AM152%20Orphan%20Drug.html

 

 

This entry was posted in Uncategorized. Bookmark the permalink.

One Response to April 19 2011 Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis

  1. Cortez Arbry says:

    Very interesting subject , thankyou for putting up. “Integrate what you believe into every single area of your life.” by Meryl Streep.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>